Categories
Change Password!
Reset Password!
Eluxadoline
appears to be a promising therapeutic agent to manage patients suffering from
diarrhea-predominant irritable bowel syndrome (IBS-D).
A recent study published in “Current Medical Research and Opinion” stated that in primary care settings, IBS-D can be appropriately treated in the absence of alarm features. During therapy selection, the risks and advantages of pharmacologic interventions should be weighed. Jennifer Jones et al. undertook this study to summarize the current recommendations for diagnosing IBS-D and offer a brief overview of the available therapeutic choices, emphasizing a novel United States Food and Drug Administration (FDA)-approved agent, eluxadoline.
Using PubMed, the literature on IBS-D was
evaluated up to January 2020, with key search terms incorporating
‘eluxadoline’, ‘IBS-D diagnosis’, and ‘IBS-D management’. It was noted that
effective treatment of IBS-D requires a personalized management strategy. To
adequately guide treatment, the evidence-based therapeutic options endorsed by
the American College of Gastroenterology and the American Gastroenterological
Association can be utilized. Lifestyle and dietary modifications, including
suitable hydration, lowering alcohol and caffeine consumption, and improving
soluble fiber consumption may alleviate the symptoms.
Over-the-counter medications like loperamide are commonly suggested and may improve rectal urgency and stool frequency. But, mixed results have been noted for the outcome of abdominal pain. Numerous off-label prescription medicines are valuable to treat IBS-D, including antispasmodics, tricyclic antidepressants, and bile acid sequestrants. For IBS-D, three prescription medications have been granted FDA-approval: eluxadoline, alosetron, and rifaximin.
Current Medical Research and Opinion
Management of irritable bowel syndrome with diarrhea: focus on eluxadoline
Jennifer Jones et al.
Comments (0)